The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
ApexOnco Front Page
Recent articles
6 September 2024
The depressed company could use Mylotarg as a stepping stone in AML.
22 August 2024
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
21 August 2024
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
21 August 2024
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
21 August 2024
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
20 August 2024
Claudin18.2 is out, but the US big pharma opts in to a new project.
19 August 2024
The company sticks with EZH2, despite others adding EZH1 inhibition.